Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses his research into the progression of monoclonal gammopathy (MGUS) into multiple myeloma (MM), and the findings which indicate that risk assessment needs to be carried out more frequently. He also highlights how not all MGUS goes through a smoldering myeloma phase. This interview took place at the International Myeloma Workshop (IMW) 2019, in Boston, MA.